October 17, 2016
New Report: Regulatory Convergence Key to Ensuring Ongoing Supply of Generic Prescription Medicines in Canada
Toronto, October 17, 2016 – Greater regulatory convergence is needed to ensure a consistent supply of safe, effective and high-quality generic medicines in Canada, according to a new study prepared by Deloitte LLP and commissioned by the Canada Generic Pharmaceutical Association (CGPA).
September 12, 2016
New report: Canadian R&D-to-Sales Ratio for Brand-name Drug Companies Less than Half of 10% Commitment
Toronto, September 12, 2016 – Brand-name drug companies’ research and development spending as a percentage of sales in Canada is less than half of the 10% the industry committed to when their periods of market exclusivity were increased in 1987, according to the most recent annual report from the federal government’s Patented Medicine Prices Review Board (PMPRB).
February 9, 2016
Toronto, February 9, 2016 – A new report released today by the federal government’s Patented Medicine Prices Review Board (PMPRB) highlights the success achieved by Canada’s provincial and territorial governments through their agreement with the Canadian Generic Pharmaceutical Association (CGPA).